Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Buys $252,875.00 in Stock

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was purchased at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the acquisition, the chief executive officer owned 512,500 shares in the company, valued at $10,367,875. This represents a 2.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Damora Therapeutics, Inc. Common Stock Trading Up 3.0%

Shares of DMRA stock opened at $21.28 on Thursday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $3.50 and a 12 month high of $38.33. The firm has a market capitalization of $1.31 billion, a PE ratio of -6.31 and a beta of 1.46. The firm has a fifty day simple moving average of $27.76 and a two-hundred day simple moving average of $26.17.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.06. On average, equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Braidwell LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth about $42,146,000. Seven Fleet Capital Management LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at about $7,398,000. Squarepoint Ops LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $303,000. Finally, Arizona State Retirement System purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth about $260,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on DMRA shares. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday. Guggenheim raised their price target on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, September 25th. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Finally, TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Damora Therapeutics, Inc. Common Stock currently has an average rating of “Buy” and an average price target of $46.50.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.